-
PSYCHOSOCIAL AND SUPPORTIVE INTERVENTIONS FOR CAREGIVERS OF INDIVIDUALS WITH DEMENTIA: A SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM -
DISMANTLING BARRIERS IN PATIENT-LED RESEARCH: UTILIZING AN AI-ENHANCED ACCESS-CENTERED RESEARCH MODEL TO EVALUATE THE INTEGRATION OF PATIENT-REPORTED OUTCOMES IN FDA ORPHAN DRUG APPROVALS
Mar 18, 2026, 21:38 PM -
INCORPORATING REAL-WORLD EVIDENCE (RWE) USING A REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) AUGMENTS TRADITIONAL SLRS: CASE STUDY IN NON-SMALL-CELL LUNG CANCER (NSCLC)
Mar 18, 2026, 21:38 PM -
REAL-WORLD DATA IN ORPHAN DRUG APPROVALS: A COMPARATIVE ANALYSIS OF THE UNITED STATES, CHINA, AND JAPAN
Mar 18, 2026, 21:38 PM -
INCIDENCE AND COSTS OF SECONDARY STROKE EVENTS IN PATIENTS WITH ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK OF NON-CARDIOEMBOLIC ORIGIN
Mar 18, 2026, 21:38 PM -
COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF THE TRANSCATHETER PULMONARY VALVE VERSUS SURGICAL REPLACEMENT FOR RVOT DYSFUNCTION IN MEXICO
Mar 18, 2026, 21:38 PM -
THE ECONOMIC BURDEN ON FAMILIES OF CHILDREN WITH TYPE 1 SPINAL MUSCULAR ATROPHY IN BRAZIL
Mar 18, 2026, 21:38 PM -
COVERAGE COMPLETENESS AND TREATMENT COST ESTIMATION FOR ADMINISTERED DRUGS IN US COMMERCIAL PAYER PRICE TRANSPARENCY DATA
Mar 18, 2026, 21:38 PM -
CUSTOMIZATION OF A LARGE LANGUAGE MODEL APPROACH TO CAPTURE PSA AND IMAGING DERIVED REAL-WORLD PROGRESSION EVENTS IN PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
BORROWING STRENGTH WITHOUT BORROWING BIAS IN ONCOLOGY USING POWER PRIORS AND COMMENSURATE PRIORS FOR LONG TERM OVERALL SURVIVAL EXTRAPOLATION
Mar 18, 2026, 21:38 PM -
PROVISIONAL PRICING IN MEDICINE POLICY: GLOBAL BENCHMARKING
Mar 18, 2026, 21:38 PM -
REAL-WORLD ANALYSIS OF TREATMENT DELAYS IN METASTATIC NON-SMALL LUNG CANCER: DEMOGRAPHIC, CLINICAL AND PAYER DRIVERS
Mar 18, 2026, 21:38 PM -
IMPROVING EARLY DETECTION OF COLORECTAL CANCER THROUGH COMMUNITY PHARMACY ENGAGEMENT: EVIDENCE FROM A SYSTEMATIC REVIEW OF FECAL IMMUNOCHEMICAL TEST-BASED STRATEGIES
Mar 18, 2026, 21:38 PM -
OPTIMIZING ENDPOINTS FOR CRSWNP BIOLOGIC TRIALS: REGULATORY, HTA, AND PATIENT-CENTERED EVIDENCE REQUIREMENTS
Mar 18, 2026, 21:38 PM -
IMPACT OF MEDICATION CLUSTERS ON POST-DISCHARGE ADVERSE DRUG EVENTS AND HEALTHCARE UTILIZATION AMONG OLDER ADULTS
Mar 18, 2026, 21:38 PM -
DELAYED EFFECT APPROACH TO RESOLVE THE CARER QALY TRAP
Mar 18, 2026, 21:38 PM -
CRITICAL APPRAISAL OF PATIENT ENGAGEMENT FRAMEWORKS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) AND HEALTH TECHNOLOGY ASSESSMENT (HTA)
Mar 18, 2026, 21:38 PM -
SURVEILLANCE OF ADVERSE DRUG REACTIONS TO TRADITIONAL CHINESE MEDICINES: A REAL-WORLD ANALYSIS FROM SHENZHEN, CHINA
Mar 18, 2026, 21:38 PM -
PREDICTING PROSTATE CANCER INCIDENCE USING A LARGE, NATIONAL U.S. ELECTRONIC HEALTH RECORDS (EHR) DATABASE
Mar 18, 2026, 21:38 PM -
TREATMENT PATTERNS AND HEALTHCARE COSTS IN PATIENTS WITH SMALL-CELL LUNG CANCER IN SOUTH KOREA: A NATIONWIDE REAL-WORLD STUDY
Mar 18, 2026, 21:38 PM
